TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00041288
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03239158
Drug: Life information rehabilitation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Study: NCT02484690
Drug: Sham Procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in treatment arm D at applicable visits to maintain masking.
Study: NCT01448031
Drug: Acetylsalicylzuur Apotex Cardio
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple doses administered on Day 1 to 5
Study: NCT03783091
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single IV administration of saline
Study: NCT00384891
Drug: Bacillus Calmette-Guérin
Normalized name: Bacillus Calmette-Guérin (BCG) vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation with BCG (Bacillus Calmette-Guérin)
Study: NCT00309738
Drug: simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01847001
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: (Non-experimental) Doxorubicin will be given as a 510 minute intravenous infusion (IV) in a dose of 60 mg/m2; cyclophosphamide will be given as a 3060 minutes intravenous infusion (IV) in a dose of 600 mg/m2 based on BSA. This chemotherapy regimen will be given every 2 weeks for total of 8 weeks or 2 months.
Study: NCT01847001
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: (Non-experimental) Doxorubicin 60 mg/m2 IV over 5-10 minutes, Cyclophosphamide 600 mg/m2 IV infusion over 30-60 minutes. The first cycle should be initiated with 3 weeks after the last paclitaxel and/or trastuzumab/pertuzumab dose.
Study: NCT01847001
Drug: Premedication
Approvals — FDA: no, EMA: no, PMDA: no
Description: As premedication to prevent some of the side effects associated with paclitaxel, you will also receive dexamethasone (Decadron) in a dose of 10 mg, diphenhydramine (Benadryl) in doses of 2550 mg, and an H2 blocker (eg. ranitidine 50 mg or equivalent) 3060 minutes before each paclitaxel infusion. If no hypersensitivity reactions are experienced, dexamethasone may be reduced in increments of 2 mg per week per dose (until a minimum of 2 mg has been reached).
Study: NCT01847001
Drug: Anti-nausea therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: In addition to doxorubicin, you will receive an anti-nausea therapy and dexamethasone about 3060 minutes before AC chemotherapy.
Study: NCT02611752
Drug: CAM2038
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAM2038 subcutaneous injection
Study: NCT01810926
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6
Study: NCT01810926
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11
Study: NCT02235519
Drug: Azilsartan 40 mg.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take 40 mg of azilsartan during 12 weeks
Study: NCT02462070
Drug: IDP-118 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotion
Study: NCT02462070
Drug: IDP-118 Vehicle Lotion
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotion
Study: NCT00321711
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the control group will receive a placebo subcutaneous injection on a weekly basis during the 4 cycle treatment period.
Study: NCT00133302
Drug: Standard CHOP
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00133302
Drug: Bi-CHOP (dose intensified CHOP)
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00324415
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1000 mg/m2/day by continuous intravenous infusion on Days 1-4 (cycle 1) and Days 29-32 (cycle 2)
Study: NCT00624871
Drug: Ascorbic acid (vitamin C)
Normalized name: Ascorbic acid (vitamin C), plain
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV, 100 mg/kg/day, every day, for 3 days
Study: NCT00624871
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PO, 10 mg/kg on day 1, 5 mg/kg/day on days 2 and 3 of life
Study: NCT00624871
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00728559
Drug: bupivacain 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: trocar site injection
Study: NCT05064904
Drug: never received RAAS blockers or received RAAS blockers before AKI.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enrollees who are not received renin-angiotensin-aldosterone blockers (RAAS) are randomly assigned to slow kidney function progression by adding RAAS blockers by receiving at least defined daily dose equal to Losartan 50mg or Captopril 25mg bid. The acute kidney disease (AKD) consultation should be transferred at least one time within 90 days after index hospital discharge after withdrawing from dialysis requiring AKI (AKI-D).~All enrolled patients are randomly referred to receive comprehensive multidiscipline consultation targeting a glycated hemoglobin level of less than 7.0%, systolic blood-pressure, target, \<130 mm Hg, low density lipid (LDL) less than 100mg/dL and control of hyperuricemia less than 7.2mg/deal in male as well as 6.1mg/dl in females. We suggest to adherence to low protein diet achieve the goal of hemoglobin more than 11g/L at 180 day after index discharge.
Study: NCT02003365
Drug: FX006 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release formulation
Study: NCT02003365
Drug: FX006 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release formulation
Study: NCT02003365
Drug: TCA IR 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release formulation
Study: NCT02504996
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 100 ml normal saline
Study: NCT00891462
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-matched placebo, oral inhalation twice per day for 12 weeks of treatment
Study: NCT03361956
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive matching placebo tablet orally.
Study: NCT01319357
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: orally for 6 weeks
Study: NCT00451451
Drug: BG00012
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00451451
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00790374
Drug: BN83495 (Cohort 1)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg daily BN83495 for 28 days
Study: NCT00790374
Drug: BN83495 (Cohort 2)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg daily BN83495 for 28 days
Study: NCT00145704
Drug: bisphosphonate therapy (risedronate)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisphosphonate therapy given to patients with growth hormone deficiency
Study: NCT00310427
Drug: LY686017
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg administered orally on a daily basis
Study: NCT00310427
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered on a daily basis
Study: NCT04140006
Drug: BMP Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flapped surgery for insertion of dental implant with topical application of BMP gel
Study: NCT03325647
Drug: Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in one arm will be randomized to receive testosterone cypionate 200 mg/ml intramuscularly every 4 weeks for a total of three doses after visit 1, and receive placebo injectable saline for the same duration starting at visit 2. Subjects in the other arm will be randomized to receive placebo injectable saline every 4 weeks for a total of 3 doses after visit 1, and testosterone cypionate 200 mg/ml intramuscularly for the same duration starting at visit 2.
Study: NCT03325647
Drug: Placebo injectable saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in one arm will be randomized to receive testosterone cypionate 200 mg/ml intramuscularly every 4 weeks for a total of three doses after visit 1, and receive placebo injectable saline for the same duration starting at visit 2. Subjects in the other arm will be randomized to receive placebo injectable saline every 4 weeks for a total of 3 doses after visit 1, and testosterone cypionate 200 mg/ml intramuscularly for the same duration starting at visit 2.
Study: NCT01303328
Drug: C1
Normalized name: PC1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local application of the experimental gel or placebo gel.
Study: NCT00214643
Drug: clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/kg
Study: NCT01874743
Drug: Rosuvastatin 20 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients must take 20mg/day of rosavastatin during 3 months
Study: NCT03836703
Drug: Feroglobin single daily use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feroglobin single daily use ( IRON FUM\&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE ) to prevent iron deficiency anemia during pregnancy from 14 weeks gestation going on.
Study: NCT03836703
Drug: Feroglobin twice daily dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feroglobin twice daily dose ( IRON FUM\&POLYSAC#1/FA/MV NO.18 162 Mg-115.2 Mg (106 Mg Iron)-1 Mg ORAL CAPSULE ) to prevent iron deficiency anemia during pregnancy from 14 weeks gestation going on.
Study: NCT04449887
Drug: Xiangsha Liujunzi granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: A traditional Chinese medicine compound, taken three times a day, one bag at a time, for a total of 28 days
Study: NCT02161952
Drug: Matched equivalent placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03347188
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to fremanezumab will be administered per schedule specified in the arm.
Study: NCT03657446
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo infusion
Study: NCT01114152
Drug: AZD9742
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Formulation
Study: NCT01114152
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV Formulation
Study: NCT00736957
Drug: Tramadol Hydrochloride (HCL) plus Acetaminophen (JNS013)
Normalized name: acetaminophen / tramadol hydrochloride Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg (JNS013) one or two tablets will be given orally four times daily (maximum dose is 8 tablets per day) for 4 weeks during treatment period 1 (restrictions on concomitant treatments will be established) and for 48 weeks during treatment period 2 (permitting modifications to the concomitant drugs/therapies). The dosing interval will be of at least 4 hours.
Study: NCT01232231
Drug: pharmacological decolonization treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine gluconate 4% body scrub and 2% shampoo daily PLUS mupirocin 2%, fusidic acid 2%, or chlorhexidine gluconate 0.2% intranasally bid PLUS trimethoprim-sulfamethoxazole 160/800mg po bid or doxycycline 100mg po bid all for 7 days
Study: NCT00935987
Drug: CYT387
Approvals — FDA: no, EMA: no, PMDA: no
Description: For the Part 1 dose-escalation portion of the study, patients will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 100 mg/day. CYT387 will be orally self-administered as a single daily dose beginning on Day 1 of the study, and thereafter at approximately the same time each day of the 28-day cycle. It is recommended that all doses be preceded by a 2-hour fast from food and beverages, and be followed by a 1-hour post-dose fast from food and beverages.~Twenty additional patients will be assigned to a 150 mg BID (twice daily) dosing schedule. CYT387 will be orally self-administered twice-daily with doses approximately 10-12 hours apart beginning on Day 1 of the study, and thereafter at approximately the same times each day of the 28-day cycle.~For the Part 2 dose confirmation portion of the study, patients will be assigned to either 150 mg or 300 mg QD (once daily) dose groups.
Study: NCT02231918
Drug: MIRAPEX® - low
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02231918
Drug: MIRAPEX® - medium
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02231918
Drug: MIRAPEX® - high
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04045548
Drug: Dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
Study: NCT04045548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
Study: NCT01692158
Drug: Heparin, Low-Molecular-Weight
Approvals — FDA: no, EMA: no, PMDA: no
Description: single subcutaneuous administration of 40 mg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
Study: NCT00809848
Drug: AGN-210669 ophthalmic solution, 0.075%
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.
Study: NCT00809848
Drug: AGN-210669 ophthalmic solution, 0.05%
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-210669 non-preserved ophthalmic solution, 0.05%. One drop in both eyes each morning once-daily for 2 weeks.
Study: NCT00809848
Drug: AGN-210669 ophthalmic solution, 0.025%
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks.
Study: NCT00809848
Drug: AGN-210669 vehicle ophthalmic solution
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks.
Study: NCT02160990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo subcutaneously twice daily for 30 days
Study: NCT01554085
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00745251
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT02666430
Drug: Lantus®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01688037
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03035227
Drug: Anti-Arrhythmics
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-Arrhythmic drugs that are deemed to be appropriate for the given participants's arrhythmia by the treating physician.
Study: NCT01420653
Drug: Maxigesic 325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxigesic USA (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day with food for 48 hours
Study: NCT01420653
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 325 mg, 3 tablets four times a day, with food for 48 hours
Study: NCT01420653
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 97.5mg, three tablets four times a day, with food for 48 hours.
Study: NCT01420653
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo, three tablets four times a day, with food for 48 hours
Study: NCT01654861
Drug: Gemcitabine, Intravenous and oral Ascorbic Acid (Vitamin C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weeks 1,2,3: IV Gemcitabine 1000 mg / m² over 30 minutes followed by HDIVC 1.2 g / kg: 1.2 g/kg over 90 minutes for a dose ≤90 g and over 120 minutes for a dose \>90g followed by 0.3 g / kg over 120 minutes; Week 4: no treatment.
Study: NCT03004196
Drug: Probiotic Toothpaste
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: G.D Probiotic Toothpaste bacteriocin Lactic Acid Bacteria
Study: NCT03004196
Drug: Dr. Reddy's Clohex
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.20% Chlorhexidine Mouthwash
Study: NCT04499976
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: placebo then misoprostol Drug: Placebo placebo for 3 days
Study: NCT02600351
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90/400 mg FDC tablet administered orally once daily
Study: NCT01813110
Drug: 4 g prescription omega-3 concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks
Study: NCT01813110
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: olive oil
Study: NCT02298985
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day (3 capsules/day) for 6 months
Study: NCT02760030
Drug: Aromatase Inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT00545337
Drug: Insuline glulisine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03982849
Drug: silymarin 0.7% cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin is a plant derived flavonoid, extracted from fruits and seeds of milk thistle.
Study: NCT03383471
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control
Study: NCT04512170
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single or Mulltiple doses up to 10 days
Study: NCT00994318
Drug: Oral Iron (Ferrous sulphate)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00533923
Drug: Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous
Study: NCT00589901
Drug: capecitabine and cyclophosphamide
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capecitabine 1000 mg/m2 oral Bid d1-14~cyclophosphamide 65 mg/m2 oral Qd d1-14
Study: NCT00657449
Drug: valdecoxib
Normalized name: Valdecoxib
DrugBank: Valdecoxib (DB00580)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: valdecoxib 80 mg (two 40 mg tablets) by mouth on Day 1 and valdecoxib 40 mg tablet once daily on Days 2-8
Study: NCT00657449
Drug: rofecoxib
Normalized name: Rofecoxib
DrugBank: Rofecoxib (DB00533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: rofecoxib 50 mg (two 25 mg capsules) by mouth once daily for 8 days
Study: NCT00395772
Drug: (LMW) Heparin + Vitamin K Antagonist
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Molecular Weight (LMW) Heparin + Vitamin K Antagonist (VKA) for 5 days, then VKA only for the rest of 12 weeks
Study: NCT02706054
Drug: Meloxicam
Normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients received an IM injection of meloxicam near the nerve root (periradicular)
Study: NCT01884623
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01816698
Drug: Taurine granule
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 package(1.6g taurine granule) once a day after meals, 12 weeks
Study: NCT01816698
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 1 package once a day after meals, 12 weeks
Study: NCT04137432
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo nasal sprays contains identical ingredients except for the peptide itself.
Study: NCT01967433
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02702206
Drug: corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: under US guidance, 2ml triamcinolone (1ml/10mg), 0.5ml distilled water and 1ml 1% lidocaine
Study: NCT02702206
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: under US guidance, 2.5ml normal saline (placebo group). 0.5ml distilled water and 1ml 1% lidocaine
Study: NCT02758366
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02938494
Drug: IDP-123 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lotion
Study: NCT02938494
Drug: Vehicle Cream
Normalized name: vehicle cream base no.160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream
Study: NCT03633617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT01543971
Drug: TXA127
Approvals — FDA: no, EMA: no, PMDA: no
Description: TXA127 : 300mcg/kg per day for 5 days, injection
Study: NCT02415959
Drug: Creon® (DR/GR)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00323583
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00323583
Drug: glutathione
Normalized name: Glutathione
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04612582
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Bortezomib (d 1, 8, 15, 22,1.3mg / m2, subcutaneous injection); cyclophosphamide (d 1, 2,900mg / m2, intravenous drip); dexamethason (d 1, 2, 8, 9,15, 16, 22, 23, 20mg, oral/intravenous injection) as a course of treatment, patients will complete six courses of treatment after entering the group, the overall observation time is one year after the end of treatment.
Study: NCT02736994
Drug: PIP toothbrush cleaner® (Chrisal, Lommel, Belgium).
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic
Study: NCT02736994
Drug: Corega Tabs Anti-bacteria®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cleansing tablet -Corega Tabs Anti-bacteria® (GlaxoSmithKline Consumer Healthcare SA, Genval, Belgium)